Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Jahr

2022

Autoren

Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T.

Verlag

Mult Scler. 2022 Apr;28(5):842-846.

Link

https://doi.org/10.1177/13524585211061335

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis